9 September 2022 in Journal of Drug Delivery Science and Technology
18 August 2018 in Journal of Medical Engineering & Technology
Lateral ankle sprain is one of the most common ankle injuries, especially in sports. When not treated properly, chronic ankle instability (CAI) may develop causing recurrent sprains and permanent damage to ankle ligaments. In this study, the design, implementation and validation of a smart wearable device connected to a smartphone application is described. This device can predict and prevent the occurrence of ankle sprain. Prediction of potentially harmful motion is achieved by continuous monitoring of ankle kinematics using inertial motion sensors. Detection of such a motion immediately triggers electrical stimulation of the peroneal muscles causing foot dorsiflexion, and hence prevents potential injury. The proposed device has the advantage of having a very short response time of eight milliseconds which is sufficient to halt the sprain motion. Laboratory validation testing using a custom designed trapdoor showed an accuracy of 96% in detecting and correcting hazardous motion. Furthermore, this device complies well with the design constrains of a wearable device such as small size and low power consumption. It is also low cost and unobtrusive due to the wireless connection between all components. Future work is recommended to test the clinical effectiveness of the proposed device in patients with CAI.
1 June 2020 in Journal of Photochemistry and Photobiology
27 September 2021 in Journal of Advances in Medicine and Medical Research
GAGhadah Mahmoud Alghzaly
MAMohammed Mohammed Albedawey
Mohammed Mohammed Albedawey
Background: One of the members of Insulin-like Growth Factor Binding Protein family is IGFBP-2 that binds to the Insulin-like Growth Factor (IGF) receptors to regulate IGF biological activities. In nephrotic syndrome IGFBP-2 has also been reported to be increased in children and IGFBP-2 considers as predictor for longitudinal deterioration of kidney function in Type 2 Diabetes. The aim of the work was to assess insulin like growth factor binding protein-2 as a marker for activity of lupus nephritis. Methods: A cross-sectional study was carried out on 80 subjects and was divided on: Group1: 60 patients with Systemic lupus erythematosus which were subdivided into: (a) 40 Systemic lupus patients with nephritis. (b) 20 Systemic lupus patients without nephritis. Group 2: 20 healthy persons as control (Healthy controls). Results: there were statistically significant difference in ILGRFBPs2 P1, P2 while P3 was insignificant, Regarding the Systemic Lupus Erythematosus Disease Activity Index (SLEDI) score, there was significant difference between group IA and IB while statistically significant positive correlation between ILGFBPs2 and renal SLEDI score. Regarding ILGFBPs2, Anti-ds DNA Ab titer, renal biopsy classes and activity index, there was a statistically significant positive correlation. Regarding chronicity index and renal SLEDI score, there was insignificant correlation. Conclusion: Serum IGFBP‐2 is a promising biomarker for lupus nephritis, reflecting disease activity and chronicity changes in renal pathology.